AbbVie to Develop New COVID-19 Treatment

“Another big biopharmaceutical company has joined the crowd working to develop effective treatments for COVID-19. AbbVie (NYSE:ABBV) has partnered with Harbour BioMed, Utrecht University, and Erasmus Medical Center to develop 47D11, an antibody that blocks the SARS-CoV-2 coronavirus that causes COVID-19.”

Abbvie Stock Information

Full Motley Fool article here:

$ABBV Stock is currently priced at $93.85 cents.

Their current market cap is $165 billion dollars.

Abbvie stock 52 week high is and 52 $97 dollars and week low is $62 dollars.

If you are looking for a dividend, they currently have a payment of 5% which is a great yield for dividend investors.

$ABBV reported earnings of over $8 billion dollars in the quarter of March 2020.

ABBVIE Stock Analysis : A Value Investors Analysis of ABBVIE

ABBVIE Investor Relations Page: